Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.56 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4668345 | 0.99 | HRH3 (0.55) | HRH3TBK1MMP2MMP13NOTUM | |
| SCHEMBL4667315 | 0.96 | HRH3 (0.50) | HRH3TBK1MMP2MMP13 | |
| Hydrochloric Acid SCHEMBL4668335 | 0.95 | HRH3 (0.49) | HRH3TBK1MMP2MMP13 | |
| SCHEMBL4667174 | 0.89 | HRH3 (0.53) | HRH3TBK1MMP2MMP13NOTUM | |
| SCHEMBL4781842 | 0.85 | HRH3 (0.47) | HRH3TBK1MMP2MMP13NOTUM | |
| SCHEMBL4666788 | 0.85 | HRH3 (0.47) | HRH3TBK1MMP2MMP13NOTUM | |
| SCHEMBL4668359 | 0.85 | HRH3 (0.47) | HRH3TBK1MMP2MMP13NOTUM | |
| SCHEMBL4667332 | 0.85 | HRH3 (0.51) | HRH3TBK1MMP2MMP13NOTUM | |
| SCHEMBL4667354 | 0.85 | HRH3 (0.44) | HRH3POLB | |
| Hydrochloric Acid SCHEMBL4668584 | 0.84 | HRH3 (0.46) | HRH3TBK1MMP2MMP13NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802307-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | claimed |
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | claimed |
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | HRH4, HRH3, HRH2 | HRH3 2/4885TBK1 3106/4885MMP2 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.